Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Chuanhong Zhongfeng Capsule is a Traditional Chinese Medicine (TCM) compound developed by Ren Jixue, a master of national medicine, for the treatment of acute cerebral infarction. The formulation is designed to promote the recovery of neurological function, reduce disability rates, and improve long-term prognosis in patients following a stroke. Clinical research, including Phase 1 trials, has employed 4D Label-free proteomics and PRM technology to investigate the protein-level mechanisms and identify potential biomarkers associated with its therapeutic effects. It is typically administered as an adjunct to basic clinical treatment for stroke.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Chuanhong Zhongfeng Capsule.